Clinical Trial Update: A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT [Phase 2]

View source ↗

Summary

Phase II, multi-center, non-randomized open-label study evaluating tislelizumab with AVD regimen for newly diagnosed advanced Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• AVD regimen (doxorubicin, vindesine, dacarbazine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hodgkin Lymphoma, Chemotherapy Effect | Phase 2 | Status: UNKNOWN